Impact of Proteinuria on Renal Outcomes in the BALANCE Trial

Lignende værker

• Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, a phase 3 open-label study
  af: Aleš Linhart, et al.
  Udgivet: (2023-10-01)
• P006: Long-term safety and efficacy of pegunigalsidase alfa administered every 4 weeks in Fabry disease: 2-Year interim results from BRIGHT51
  af: John Bernat, et al.
  Udgivet: (2023-01-01)
• P236: Extending the interval between pegunigalsidase alfa infusions in patients with Fabry disease: Five-year interim results from the ongoing BRIGHT51 study
  af: John Bernat, et al.
  Udgivet: (2025-01-01)
• Long-term efficacy and safety of pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease: results from up to 5 years of the BRIGHT F51 phase III, open-label extension study
  af: Myrl Holida, et al.
  Udgivet: (2026-03-01)
• Impact of Proteinuria on Renal Outcomes in the BALANCE Trial
  af: Eric L. Wallace, et al.
  Udgivet: (2026-02-01)